SAN FRANCISCO--(BUSINESS WIRE)--Theregen, Inc. has completed enrollment of its 15-patient Phase I safety trial for its Anginera™ epicardial patch on patients undergoing coronary arterial bypass graft (CABG) surgery. Paul Quadros, Theregen’s Chief Executive Officer, said, “Completion of enrollment in our Phase I Safety trial is a major accomplishment for the Company. We were particularly impressed by the depth of new blood vessel growth and enhanced ventricular wall motion under areas treated with the Anginera patch. This positions the Company for a Phase II trial to treat patients suffering from cardiac dysfunction.”
